Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 50

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 50
---
 RELATED TO THE DIVESTITURE, THE PIPE FINANCING, THE LICENSE AGREEMENT AND THE ADC PROGRAMS You should carefully consider and evaluate all of the information included in this proxy statement and the annexes attached to the proxy statement, including the risks described below . Any of these risks, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations, financial condition and prospects, which in turn could materially and adversely affect the trading price of shares of our common stock. Stockholders should keep in mind that the risks below are not the only risks that are relevant to your voting decision. Additional risks not currently known or currently material to us may also harm our business. Risks Related to the Pending Divestiture In addition to the other information contained in this proxy statement, you should carefully consider the following risk factors when deciding whether to vote to approve the Divestiture Proposal. The pendency of the Divestiture could have an adverse effect on our business and results of operations, and the failure to complete the Divestiture in a timely manner or at all could adversely affect our business, financial condition, results of operations and stock price. On December 19, 2024, we entered into the Divestiture Agreement with Kaken. Completion of the Divestiture is subject to the satisfaction of certain terms and conditions set forth in the Divestiture Agreement, including (1) the receipt of approval of the Divestiture Agreement and the Divestiture by the requisite affirmative vote of our stockholders; (2) the receipt of all consents and approvals (if any) required under any regulatory laws applicable to the Divestiture; and (3) the absence of any temporary restraining order, preliminary or permanent injunction or other judgment or order issued by any court of competent jurisdiction, any legal or regulatory restraint or prohibition by any governmental authority of competent jurisdiction, and any law enacted, entered, enforced or applied to the Divestiture, that in each case, would prevent or materially impair the consummation of the Divestiture. There is no assurance that the remaining conditions to closing the Divestiture will be satisfied before the Termination Date or at all, or that the Divestiture will be completed on the proposed terms, within the expected timeframe, or at all. The Divestiture may be delayed, and may ultimately not be completed, due to a number of factors, including:

| • |     | the failure to obtain the requisite affirmative vote of the approval of the Divestiture